NEOPHARM BEGINS PATIENT ENROLLMENT IN LE-SN38 TRIAL
NeoPharm has begun patient enrollment in a multicenter Phase II clinical trial of LE-SN38 for the treatment of patients with metastatic colorectal cancer. The company noted that this trial will seek to enroll up to 54 patients.
The National Cancer Institute-sponsored Cancer and Leukemia Group B is conducting this trial. The company said that the primary endpoint of the trial is overall tumor response rate following treatment with LE-SN38 as a second-line treatment in patients with metastatic colorectal cancer.